Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
A method for treating bisretinoid-mediated macular degeneration in a mammal afflicted therewith comprising administering to the mammal an effective amount of a compound having the structure: or an ester or a pharmaceutically acceptable salt thereof.
1. A method for treating bisretinoid-mediated macular degeneration in a mammal afflicted therewith comprising administering to the mammal an effective amount of a compound having the structure:
or an ester or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the amount is effective to lower the serum concentration of RBP4 in the mammal.
3. The method of claim 1 , wherein the amount is effective to lower the retinal concentration of a bisretinoid in lipofuscin in the mammal.
4. The method of claim 3 , wherein the bisretinoid is A2E, isoA2E, A2-DHP-PE, or atRAL di-PE.
5. The method of claim 1 , wherein the bisretinoid-mediated macular degeneration is Age-Related macular Degeneration.
6. The method of claim 1 , wherein the bisretinoid-mediated macular degeneration is Stargardt Disease.
7. The method of claim 1 , wherein the bisretinoid-mediated macular degeneration comprises the accumulation of lipofuscin deposits in the retinal pigment epithelium.
8. The method of claim 2 , wherein the amount is effective to lower the retinal concentration of a bisretinoid in lipofuscin in the mammal.
9. The method of claim 4 , wherein the bisretinoid is A2E.
10. The method of claim 4 , wherein the bisretinoid is isoA2E.
11. The method of claim 4 , wherein the bisretinoid is A2-DHP-PE.
12. The method of claim 4 , wherein the bisretinoid is atRAL di-PE.
13. The method of claim 4 , wherein the bisretinoid-mediated macular degeneration is Age-Related Macular Degeneration.
14. The method of claim 4 , wherein the bisretinoid-mediated macular degeneration is Stargardt Disease.